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Table 1
Univariable outcomes of patients who underwent allogeneic HSCT for AML,
ALL, CML, MDS who had IFI w/in 12 months pre-transplant vs. no docu-
mented IFI w/in 12 months prior to transplant (2001 to 2009)
Outcomes Pre-tx invasive
fungal infection
All others P-value
N
Eval
Probability
(95% CI)
Probability
(95% CI)
Overall survival
from transplant
825 10247
@ 1 year 54 (48-55)% 65 (64-66)% <.0001
@ 3 years 35 (31-38)% 50 (49-51)% <.0001
@ 5 years 30 (26-34)% 45 (44-46)% <.0001
Relapse 813 10146
@ 1 year 33 (29-36)% 26 (25-27) % 0.0002
@ 3 years 42 (39-46)% 35 (34-36)% <.0001
@ 5 years 45 (41-49)% 39 (38-40)% 0.0018
Treatment
related mortality
813 10146
@ 1 year 23 (20-26)% 17 (17-18)% 0.0003
@ 3 years 27 (24-30)% 22 (21-23)% 0.0046
@ 5 years 29 (26-32)% 25 (24-26)% 0.0347
Disease
free survival
813 10146
@ 1 year 45 (41-48)% 57 (56-58)% <.0001
@ 3 years 31 (28-34)% 44 (43-45)% <.0001
@ 5 years 27 (23-31)% 37 (36-38)% <.0001
Acute GVHD
(grade 2-4)
822 10224
@ 100 days 34 (31-37)% 39 (38-40)% 0.0022
Chronic GVHD 810 10098
@ 1 year 31 (28-34)% 39 (38-40) % <.0001
@ 3 years 35 (32-38)% 44 (43-45)% <.0001
@ 5 years 36 (32-39)% 45 (44-46)% <.0001
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antibody (Ab) accretion at tumor sites and gradual elim-
ination from circulation. We have used a pretargeted (P)
RIT approach employing the high-afﬁnity streptavidin
(SA)-biotin system, in which an anti-CD45 Ab-SA conju-
gate and the radioactive DOTA-biotin compound are
administered separately. After maximal accumulation of
Ab-SA conjugate in CD45þ tissues, therapeutic radiobiotin
is administered and attaches to the pretargeted Ab-SA
conjugate bound speciﬁcally to tumor cells, with
unbound radiobiotin rapidly excreted by the kidneys. We
have evaluated the safety of PRIT using an anti-CD45 Ab-
SA conjugate followed by 90Y-DOTA-biotin combined with
ﬂudarabine (FLU), 2 Gy total body irradiation (TBI) and
matched allogeneic HCT for patients with advanced acute
myeloid leukemia (AML), acute lymphoblastic leukemia
(ALL), or high-risk myelodysplastic syndrome (MDS).
Seven patients received trace labeled, dosimetric infu-
sions of 0.7 mg/kg anti-CD45 Ab-SA followed 48 hours
later by 1.3 mg/m2 of 111In-DOTA-biotin (5-10 mCi). The
biodistribution of 111In-DOTA-biotin was assessed by
serial planar gamma camera imaging at multiple time
points that revealed optimal targeting of leukemic target
tissues. Five patients then received 0.7 mg/kg anti-CD45
Ab-SA followed 48 hours later by 1.3 mg/m2 DOTA-biotin
labeled with a therapeutic amount of 90Y (62-112 mCi,
median 75 mCi) based on OLINDA organ based dosimetry
from the 111In-DOTA-biotin images. Of the two patients
who did not receive therapeutic infusions, one developed
cellulitis and the other was diagnosed with bladder
carcinoma. Approximately one week after 90Y-DOTA-
biotin PRIT, FLU was administered at 30 mg/m2/day for 3
consecutive days followed by TBI at a dose of 2 Gy (6-7
cGy/min) and then infusion of >2 x 106 CD34-expressing
peripheral blood stem cells/kg body weight. Two grade 3
gastrointestinal adverse events (enterocolitis, typlitis)
were identiﬁed as unexpected and considered possibly
related to PRIT, with the only grade 4 event being
cytopenias that are expected during HCT. No participants
were withdrawn from the study due to toxicities. One of
the 5 high-risk AML/MDS patients enrolled remains alive
in complete remission a year after protocol treatment.
The other 4 patients died of progressive disease with
a median time to relapse of 28 days (range 12-155).
Whether this approach will reduce post-transplant
relapse remains to be determined, but further dose
escalation is clearly necessary.29
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Invasive fungal infections (IFI) are associated with a high
mortality rate in patients undergoing hematopoietic stem
cell transplantation (HSCT). However, with availability of
new antifungal agents with lower toxicity proﬁles and
implementation of reduced intensity transplants (RIT),
patients with previously documented, proven or probable IFI
are increasingly undergoing HSCT. Recognizing these prac-
tice changes, the clinical outcomes of patients with pre-
existing IFI, diagnosed prior to allogeneic HSCT, (n¼ 825)
were compared to a similar cohort of patients from the same
HSCT centers over the past decade without proven or prob-
able pre-transplant IFI (n¼10,247), for outcomes of treat-
ment related mortality (TRM), relapse rates, overall survival
(OS), disease free survival (DFS) and the development of
post-transplant IFI. Primary analysis focused on outcomes
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AML and ALL patients receiving myeloablative conditioning
extending from 1995 to 2009, prior to availability of novel
antifungal agents, and the emergence of PBSC allografts.
Patients with pre-transplant IFI were older, have lower
performance status, have advanced disease, carry the diag-
nosis of AML, receive a cord blood transplant, receive RIT,
receive mold-active fungal prophylaxis and be transplanted
more recently. Aspergillus and Candidal infections were the
most commonly identiﬁed pre-transplant IFI and 68% of
patients presented with pulmonary involvement. Uni-
variable outcomes analysis reveals lower 1-year, 3-year, and
5-year DFS and OS for patients with pre-transplant IFI
(Table 1). Relapses were higher in this cohort and there was
a trend to increased TRM. The probability of post-transplant
fungal infection was 24% for the study group and 17% for the
control group (p <0.001). Interestingly, cause of death was
associated with a greater likelihood of having recurrent/
persistent disease. Infectious mortality causes were only
slightly increased (13 vs 9%) between the study group and
the control group. With regard to the 2o analysis comparing
patients with pre-transplant IFI diagnosed between 1995
-2000 vs 2001-2009, TRM @ 1, 3, 5 yrs was signiﬁcantly
higher with associated reduction in OS and DFS for the early
cohort. However, there were no observable differences in IFI
post-transplant and in relapse rates.
Conclusions: Documentation of pre-HSCT IFI is associated
with lower DFS and OS after allogeneic HSCT. However,
mortality is most inﬂuenced by patients withmore advanced
disease status than infectious etiologies. Treated pre-trans-
plant IFI does not appear to be a contraindication to alloge-
neic HSCT.
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Background: While CBT is a known risk factor for HHV-6
reactivation, the level of viremia associated with a high risk
of HHV-6 encephalitis is not established and the association
with CBT outcomes is controversial.
Methods: We analyzed the nature of HHV-6 reactivation in
125 double-unit CB recipients who were transplanted for
hematologic malignancies from 2/2006-3/2012. Viremia was
measured by quantitative PCR of plasma HHV-6 DNA (lower
detection limit 100 DNA copies/ml).
Results: Of 125 patients (median age 42 years, range 1-
69), 93 (74%) received myeloablative and 32 (26%)
received non-myeloablative conditioning followed by 4-6/
6 HLA-A,B antigen, -DRB1 allele matched CBT for the
treatment of AML (n ¼ 43, 34%), ALL (n ¼ 24, 19%), MDS/
CML/ other leukemia (n ¼ 12, 10%), or lymphoma/ CLL (n¼ 46, 37%). No patient received anti-thymocyte globulin
(ATG). One-hundred and seventeen (94%) patients reac-
tivated HHV-6 (median peak 7,600 copies/ml, range 100-
160,000) at a median of 20 days (range 10-59). The
median time to peak viremia was 23 days (range 12-62)
and the median viremia duration was 8 days (range 1-60
days). Fifty-one patients (41% of total, 44% of viremic
patients) developed HHV-6 > 10,000 copies/ml (median
peak 31,200 copies/ml at 20 days, range 12-57). Only 6
patients (5% of total, 5% of viremic patients) had HHV-6 >
100,000 copies/ml (median peak 130,000 copies/ml at 19
days, range 14-29). HHV-6 encephalitis occurred in 2
patients (1.6%, peak viremias 13,000 and 118,000, respec-
tively); 1 died from encephalitis and the other recovered
with therapy. Four other viremic patients had HHV-6
isolated from bronchoalveolar lavage but did not meet
criteria for HHV-6 pneumonia. Deﬁning high level viremia
as > 10,000 copies/ml in days 14-60, viremia was not
associated with diagnosis or conditioning, engrafting unit-
recipient HLA-match or TNC, CD34þ, CD3þ cell doses.
Treating viremia as a time-dependent covariate in Cox
regression analysis, no association was found between
viremia and neutrophil or platelet engraftment. There was
also no association between viremia and CMV reactivation,
day 100 grade II-IV aGVHD, day 100 TRM, relapse, or
overall survival. If high level viremia was deﬁned as >
25,000 copies/ml (n ¼ 31, the highest peak viremia
quartile days 14-60), no associations with CBT outcomes
were detected. Finally, 24 patients had a second viremia
(median onset day 49, range 100-27,300) without obvious
sequelae.
Conclusions: Nearly all our CBT recipients reactivate HHV-6.
While the incidence of end-organ disease is low, possibly due
to our exclusion of ATG from the conditioning, our under-
standing of the signiﬁcance of HHV-6 viremia is incomplete.
We are currently evaluating anti-viral treatment responses,
and ultimately a prospective trial is needed to better deﬁne
the causality between HHV-6 viremia and transplantation
outcomes, and to investigate the risk-beneﬁts of pre-emptive
therapy.31
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Background: Treatment remains a challenge for systemic
light chain amyloidosis (AL). Autologous stem cell transplant
(AutoSCT) has been associated with long term survival.
However, a recent multicenter randomized study failed to
show survival beneﬁt for AutoSCT perhaps due to high non-
relapse mortality (NRM). Here we present a comparison of
AutoSCT to other conventional therapies in AL patients
treated at our institution with a 14-year follow up.
Methods: A total of 2018 cases were identiﬁed upon
pathology review from 1998-2012. AL was conﬁrmed in 264
patients; primary amyloidosis (PA) in 147 pts and multiple
myeloma with amyloidosis (AM) in 110 patients; solitary
